Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS
(1)
,
(2, 3)
,
(4)
,
(5)
,
(6)
,
(1)
,
(7)
,
(8)
,
(9)
,
(10)
,
(11)
,
(4)
,
(12)
,
(13)
,
(1)
,
(1)
,
(1)
,
(1, 14)
,
(2, 15)
,
(1, 16, 2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16